Protocolo clínico para prescrição farmacêutica de contraceptivos hormonais em âmbito institucional

Abstract

Unwanted pregnancies are a worldwide public health problem. In Brazil, the rate of unintended pregnancies is over 50% and the pregnancy profile of this nature is associated with a greater likelihood of obstetric complications, depression and postpartum stress. In this sense, thinking of improving access to hormonal contraception, the State of Oregon, in the United States, was the first region in that country to regulate the pharmaceutical prescription of hormonal contraceptives. In Brazil, the Federal Pharmacy Council allows prescription of prescription drugs through a collaboration agreement with a health institution or prescribing professional, and the development of a clinical protocol. Therefore, thinking about increasing the access and the rational use of hormonal contraceptives, this study aimed to develop a clinical protocol for pharmaceutical prescription of hormonal contraceptives, oral and injectable, to be carried out at the school pharmacy of the Federal University of Paraíba. For this, a collaboration agreement was made with the Reference Center for Health Care at UFPB, meeting the requirements of resolution 586/2013 of the CFF. For the elaboration of the protocol, bibliographic research was carried out to raise the main contraindications to the use of hormonal contraceptives. Subsequently, a questionnaire for screening and risk assessment in the use of CH and flowcharts for therapeutic decision and conduct in specific cases were developed. The collaboration agreement was signed by the coordinator of CRAS - UFPB on October 30, 2019. Therefore, the present work, through the definition of an institutional protocol, elaborates a tool to stratify the risk associated with the use of hormonal contraceptives and regularize the pharmaceutical conduct in accordance with current legislation.